This supplement takes a look at new guidelines for the treatment of TTP, the latest FDA approvals for the treatment of red blood cell and iron disorders, and more.
This supplement discusses the value of mutation testing for myeloid malignancies, reevaluates maintenance therapy in AML, and more.
This supplement takes a look at the future of chemoimmunotherapy for chronic lymphocytic leukemia, the latest FDA approvals for the treatment of lymphoid and plasma cell malignancies, and more.
This supplement explores new treatment options for hemophilia, gene therapy in nonmalignant hematologic disorders, and more.
This supplement features FDA updates for the treatment of myeloid malignancies, new questions in acute myeloid leukemia, and more.
This supplement features a look at the future of Hodgkin lymphoma treatment, the latest approvals for lymphoid malignancies, and more.
In this special edition, we take a look at the latest updates in classical hematology, from a advances in gene therapy for hemophilia to a debate about intravenous iron in pregnant women with iron-deficiency anemia, and more.
This supplement features FDA updates, clinical trials, and the latest research in myeloid malignancies.
This supplement features a look at controversies in myeloma treatment, the future of immunotherapy for lymphoma, newly approved and investigational therapies, and more.
This special edition features a closer look at immunotherapy, including the challenges and obstacles of clinical trials, the state of CAR T-cell therapy, and immunotherapies in the development pipeline.
12Page 1 of 2